Search results
Results From The WOW.Com Content Network
7-Hydroxymitragynine (7-OH) is a terpenoid indole alkaloid from the plant Mitragyna speciosa, commonly known as kratom. [2] It was first described in 1994 [3] and is a human metabolite metabolized from mitragynine present in the Mitragyna speciosa. 7-OH binds to opioid receptors like mitragynine, but research suggests that 7-OH binds with greater efficacy.
Mitragynine is an indole-based alkaloid and is one of the main psychoactive constituents in the Southeast Asian plant Mitragyna speciosa, commonly known as kratom. [4] It is an opioid that is typically consumed as a part of kratom for its pain-relieving and euphoric effects.
Mitragynine pseudoindoxyl is a rearrangement product of 7-hydroxymitragynine, an active metabolite of mitragynine. [ 1 ] Mitragynine pseudoindoxyl can be produced in the blood as a metabolite of 7-hydroxymitragynine.
[32] [11] [9] The alkaloids mitragynine and 7-hydroxymitragynine are responsible for many of the complex effects of kratom, [11] [9] but other alkaloids may also contribute synergistically. [32] The effects of both mitragynine and 7-HMG remain disputed despite substantial study. Both are partial agonists of the μ-opioid receptor.
Mitraphylline, an oxindole derivative, is an active alkaloid in the leaves of the tree Mitragyna speciosa, commonly known as kratom. [1] As a non-narcotic constituent, it also occurs to a significant amount in the bark of Uncaria tomentosa (Cat's Claw) along with a number of isomeric alkaloids.
Mitragynine pseudoindoxyl Index of chemical compounds with the same molecular formula This set index page lists chemical structure articles associated with the same molecular formula .
Acute use (1–3 days) yields a potency about 1.5× stronger than that of morphine and chronic use (7 days+) yields a potency about 2.5 to 5× that of morphine. Similarly, the effect of tramadol increases after consecutive dosing due to the accumulation of its active metabolite and an increase of the oral bioavailability in chronic use.
It was discovered in 2005 during structure-activity relationship studies into neoclerodane diterpenes, the family of chemical compounds of which salvinorin A is a member. [1] Unlike salvinorin A, which is a selective κ-opioid receptor agonist with no significant μ-opioid receptor affinity, herkinorin is predominantly a μ-opioid receptor agonist.